The information provided by is not a substitute for professional medical advice, diagnosis or treatment. The views and opinions expressed on the site do not necessarily represent those of Drugwatch. Sponsored by Wilson and Peterson, LLP with offices at 1050 30th Street NW, Washington, . 20007. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of "Fair Use" and legitimately infringes on yours or your client's copyright, we may be contacted concerning copyright matters at: [email protected]
Yasmin contains 3 mg of the progestin DRSP, which has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to a 25 mg dose of spironolactone. Yasmin is contraindicated in patients with conditions that predispose to hyperkalemia (that is, renal impairment, hepatic impairment, and adrenal insufficiency). Women receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration should have their serum potassium concentration checked during the first treatment cycle. Medications that may increase serum potassium concentration include ACE inhibitors , angiotensin –II receptor antagonists, potassium-sparing diuretics , potassium supplementation, heparin , aldosterone antagonists, and NSAIDs . Consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly. Strong CYP3A4 inhibitors include azole antifungals (. ketoconazole, itraconazole, voriconazole), HIV /HCV protease inhibitors (., indinavir, boceprevir), and clarithromycin [see CLINICAL PHARMACOLOGY ].